SCHEDULE: Marvin Slosman Discloses 5.18% Stake in InspireMD

CEO Marvin Slosman files a Schedule 13D reporting beneficial ownership of 5.18% of InspireMD, Inc. common stock.

Summary

• Marvin Slosman, CEO of InspireMD, Inc., has filed a Schedule 13D reporting beneficial ownership of 2,556,760 shares.
• This ownership represents 5.18% of the company's total issued and outstanding common stock.
• The holdings consist of a mix of common shares, restricted stock units (RSUs), and stock options granted under various equity incentive plans.
• The reporting person acquired 10,330 shares via a private placement in July 2025 for $24,998.60, with the remainder acquired through equity compensation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming the CEO's existing equity position and compliance with SEC reporting requirements.

Positives

• Alignment of interests between the CEO and shareholders through significant equity ownership.
• The majority of the stake is derived from long-term equity incentive plans, indicating management's commitment to the company's growth.

Negatives

• None identified in this filing.

Risks

• The reporting person reserves the right to change his position, including the potential disposal of shares in the open market or private transactions.
• Future changes in the CEO's strategic plans or involvement in corporate activities could influence company direction.

Future Outlook

The reporting person has no present plans or proposals regarding the company but reserves the right to review his position or propose corporate actions in the future.

Management Comments

• The Reporting Person serves as an executive officer of the Issuer and, in such capacity, may be involved in reviewing transactions involving the Issuer and may have influence over the corporate activities of the Issuer.

Industry Context

StockSavvy.ai notes that Schedule 13D filings by CEOs are standard regulatory requirements when ownership crosses the 5% threshold, typically signaling transparency regarding executive compensation and long-term alignment with company performance.

Comparison to Industry Standards

• The filing follows standard SEC disclosure requirements for beneficial ownership.
• The structure of the holdings (mix of RSUs and options) is consistent with typical executive compensation packages in the medical device sector.

Legal Proceedings

• The reporting person confirms no criminal or civil proceedings involving securities law violations in the last five years.

Related Party Transactions

• Acquisition of 10,330 shares from the Issuer in a private placement in July 2025.

Stakeholder Impact

• Provides transparency to shareholders regarding the CEO's total economic interest in the company.

Next Steps

• The reporting person may continue to acquire or dispose of shares as part of ongoing compensation or personal investment strategies.

Key Dates

Keywords

InspireMD, Schedule 13D, Marvin Slosman, Beneficial Ownership, Equity Compensation, Insider Holdings